China-based Jiangsu Trautec Medical Technology Co., Ltd. has reportedly raised nearly RMB200 million (USD205.3 million) in a Series A financing round. The round was led by Shiseido’s Ziyue Fund, with participation from Hua Fang Investment, CDH Wealth Management, and Holley Pharma. The proceeds will be directed towards investments in technology innovation and product research and development in the field of recombinant collagen biomaterials.
Company Background
Founded in 2015, Trautec focuses on the R & D, manufacturing, and marketing of new biomaterials and innovative protein/nucleic acid drugs. Its offerings cover areas such as injury repair and tissue regeneration. The company has R & D and manufacturing facilities in Changzhou, Jiangsu province, Qinghai Xining, and Hunan Changsha. It has also established joint laboratories and research institutes related to recombinant collagen with multiple universities and has conducted clinical studies with several large Class 3A hospitals in China.-Fineline Info & Tech
